Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

ABSTRACTBackground Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials.Research design and methods Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivate...

Full description

Bibliographic Details
Main Authors: Abundio Balgos, Suad Hannawi, Wen-Li Chen, Alaa Abuquta, Linda Safeldin, Aala Hassan, Ahmad Alamadi, Louie Tirador, Anjuli May Jaen, Ralph Elvi Villalobos, Chen Mo, Zi-Jing Yue, Ying Ma, Qing-Shuang Wang, Ren-Du Wen, Zheng Yao, Jia-Ping Yu, Wen-Rong Yao, Jian-Hui Zhang, Kun-Xue Hong, Yong Liu, Jing-Xin Li
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Expert Review of Vaccines
Subjects:
Safety
immunogenicity
SARS-CoV-2
heterologous booster
omicron variants
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2024.2334423

Internet

https://www.tandfonline.com/doi/10.1080/14760584.2024.2334423

Similar Items